Abstract
The choice of a Phase I contract research organization is clearly a key point for a successful strategy at this early stage of development. A survey was performed with the help of a questionnaire filled in by 36 pharmaceutical companies operating in France and sponsoring Phase I trials.
This survey addressed the following main questions: number and type of Phase I studies, information on Phase I centers, and criteria of choice for a Phase I center. Finally, the answers were compared to a similar survey performed five years earlier.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Scrip Magazine. March 1994:32-34.
Püchler K, Witte PU. The German CRO market. App Clin Trials. 1996;6(8):24–28.
Hughes, G. Criteria for choice of Phase I contract research organizations by pharmaceutical companies. Clin Trials Meta-Analysis. 1994;29(4):288.
Rosenzweig P, Bergougnan L, Brohier S, et al. Les centres de Phase I: le point de vue de l’industriel. La Lett Pharmacol. 1991;5(7):248–252.
Vogel JR, Resnich N. A case study in evaluating and selecting a CRO. App Clin Trials. 1996;6(8):30–36.
Schanlder M. A strategic role for CROs. App Clin Trials. 1994;3(9):56–64.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rosenzweig, P. Selection Criteria for Phase I Contract Research Organizations by Pharmaceutical Companies. Ther Innov Regul Sci 32, 825–830 (1998). https://doi.org/10.1177/009286159803200322
Published:
Issue Date:
DOI: https://doi.org/10.1177/009286159803200322